<DOC>
	<DOC>NCT01257204</DOC>
	<brief_summary>To identify a shorter duration of antiviral therapy (12 or 16 weeks) for the combination of daclatasvir with pegylated interferon alfa-2a and ribavirin.</brief_summary>
	<brief_title>Study in Genotype 2 or 3 Patients With Chronic Hepatitis Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Participants chronically infected with hepatitis C virus (HCV) genotype 2 or 3 No previous exposure to an interferon formulation (ie, interferon alfa, pegylated interferon alfa2a ) or ribavirin Body mass index (BMI) of 18 to 35 kg/m^2, inclusive. BMI=weight (kg)/height (m)^2 Males and females, 18 70 years of age Key Liver transplant recipients Documented or suspected hepatocellular carcinoma Evidence of decompensated cirrhosis History of chronic hepatitis B virus (HBV). Patients with resolved HBV infection may participate Current or known history of cancer Any gastrointestinal disease or surgical procedure that may impact the absorption of study drug Inability to tolerate oral medication Poor venous access Severe psychiatric disease History of chronic pulmonary disease History of cardiomyopathy, coronary artery disease (including angina), interventive procedure for coronary artery disease (including angioplasty, stent procedure, or cardiac bypass surgery), ventricular arrhythmia,, or other clinically significant cardiac disease History of or current electrocardiogram findings indicative of cardiovascular instability Preexisting ophthalmologic disorders considered clinically significant on eye History of uncontrolled diabetes mellitus Any known contraindication to pegylated interferon alfa2a or ribavirin not otherwise specified. Positive hepatitis B virus surface antigen, HIV1 or HIV2 Ab Prior exposure to any HCV direct antiviral agent (eg, HCV protease, polymerase, previous nonstructural protein 5A inhibitors) Exposure to any investigational drug or placebo</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>